Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Management of rivaroxaban or apixaban associated major bleeding with prothrombin complex concentrates: a cohort study.

Majeed A, Ågren A, Holmström M, Bruzelius M, Chaireti R, Odeberg J, Hempel EL, Magnusson M, Frisk T, Schulman S.

Blood. 2017 Aug 23. pii: blood-2017-05-782060. doi: 10.1182/blood-2017-05-782060. [Epub ahead of print]

PMID:
28835439
2.

Whole blood ristocetin-activated platelet impedance aggregometry (Multiplate) for the rapid detection of Von Willebrand disease.

Schmidt DE, Bruzelius M, Majeed A, Odeberg J, Holmström M, Ågren A.

Thromb Haemost. 2017 Jul 26;117(8):1528-1533. doi: 10.1160/TH17-02-0129. Epub 2017 Jul 6.

PMID:
28692107
3.

Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS).

Grosso G, Vikerfors A, Woodhams B, Adam M, Bremme K, Holmström M, Ågren A, Eelde A, Bruzelius M, Svenungsson E, Antovic A.

Thromb Res. 2017 Jun 24. pii: S0049-3848(17)30392-4. doi: 10.1016/j.thromres.2017.06.028. [Epub ahead of print]

PMID:
28669410
4.

Relative effects of plasma, fibrinogen concentrate, and factor XIII on ROTEM coagulation profiles in an in vitro model of massive transfusion in trauma.

Schmidt DE, Halmin M, Wikman A, Östlund A, Ågren A.

Scand J Clin Lab Invest. 2017 Oct;77(6):397-405. doi: 10.1080/00365513.2017.1334128. Epub 2017 Jun 20.

PMID:
28632435
5.

Thromboelastometry: Relation to the severity of liver cirrhosis in patients considered for liver transplantation.

Dumitrescu G, Januszkiewicz A, Ågren A, Magnusson M, Wahlin S, Wernerman J.

Medicine (Baltimore). 2017 Jun;96(23):e7101. doi: 10.1097/MD.0000000000007101.

6.

Whole blood coagulation assays ROTEM and T-TAS to monitor dabigatran treatment.

Taune V, Wallén H, Ågren A, Gryfelt G, Sjövik C, Wintler AM, Malmström RE, Wikman A, Skeppholm M.

Thromb Res. 2017 May;153:76-82. doi: 10.1016/j.thromres.2017.03.018. Epub 2017 Mar 18.

PMID:
28347811
7.

Monitoring of coagulation factor therapy in patients with von Willebrand disease type 3 using a microchip flow chamber system.

Ågren A, Holmström M, Schmidt DE, Hosokawa K, Blombäck M, Hjemdahl P.

Thromb Haemost. 2017 Jan 5;117(1):75-85. doi: 10.1160/TH16-06-0430. Epub 2016 Oct 20.

PMID:
27761577
8.

Haemostasis monitored in stored red blood cells, plasma and platelet concentrates in the proportion of 4 :  4 :  1 diluted with crystalloids and colloids.

Ågren A, Edgren G, Ambrosio D, Gryfelt G, Östlund A, Wikman A.

Blood Coagul Fibrinolysis. 2016 Apr;27(3):334-9. doi: 10.1097/MBC.0000000000000433.

PMID:
26963027
9.

The temporal pattern of postoperative coagulation status in patients undergoing major liver surgery.

Dumitrescu G, Januszkiewicz A, Ågren A, Magnusson M, Isaksson B, Wernerman J.

Thromb Res. 2015 Aug;136(2):402-7. doi: 10.1016/j.thromres.2015.05.023. Epub 2015 May 24.

10.

Strategies and outcomes of periprocedural bridging therapy with low-molecular-weight heparin in patients with mechanical heart valves.

Schulman JM, Majeed A, Mattsson E, Schulman S, Holmström M, Ågren A.

J Thromb Thrombolysis. 2015 Nov;40(4):430-6. doi: 10.1007/s11239-015-1216-4.

PMID:
25868460
11.

Detection of elevated INR by thromboelastometry and thromboelastography in warfarin treated patients and healthy controls.

Schmidt DE, Holmström M, Majeed A, Näslin D, Wallén H, Ågren A.

Thromb Res. 2015 May;135(5):1007-11. doi: 10.1016/j.thromres.2015.02.022. Epub 2015 Feb 26.

PMID:
25746367
12.

[Sickle cell anemia causes varied symptoms and high morbidity. Serious prognosis in the most common genetic disease in the world].

Kjellander C, Sennström MK, Stiller V, Ågren A.

Lakartidningen. 2015 Mar 3;112. pii: DCPM. Review. Swedish.

13.

In response.

Agren A, Wikman A, Ostlund A, Edgren G.

Anesth Analg. 2014 Dec;119(6):1453. doi: 10.1213/ANE.0000000000000431. No abstract available.

PMID:
25405698
14.

Response to comment on Ågren et al. Increased incorporation of antiplasmin into the fibrin network in patients with type 1 diabetes. Diabetes care 2014;37:2007-2014.

Agren A, Jörneskog G, Elgue G, Henriksson P, Wallen H, Wiman B.

Diabetes Care. 2014 Nov;37(11):e244. doi: 10.2337/dc14-1644. No abstract available.

PMID:
25342841
15.

Fibrin clot properties and haemostatic function in men and women with type 1 diabetes.

Tehrani S, Jörneskog G, Ågren A, Lins PE, Wallén H, Antovic A.

Thromb Haemost. 2015 Feb;113(2):312-8. doi: 10.1160/TH14-05-0404. Epub 2014 Oct 16.

PMID:
25318636
16.

In vitro combinations of red blood cell, plasma and platelet components evaluated by thromboelastography.

Agren A, Edgren G, Kardell M, Ostlund A, Wikman AT.

Blood Transfus. 2014 Oct;12(4):491-6. doi: 10.2450/2014.0285-13. Epub 2014 Jun 5.

17.

TEG® functional fibrinogen analysis may overestimate fibrinogen levels.

Agren A, Wikman AT, Ostlund A, Edgren G.

Anesth Analg. 2014 May;118(5):933-5. doi: 10.1213/ANE.0000000000000172.

PMID:
24781565
18.

Increased incorporation of antiplasmin into the fibrin network in patients with type 1 diabetes.

Agren A, Jörneskog G, Elgue G, Henriksson P, Wallen H, Wiman B.

Diabetes Care. 2014 Jul;37(7):2007-14. doi: 10.2337/dc13-1776. Epub 2014 Apr 23.

PMID:
24760258
19.

Studies of fibrin formation and fibrinolytic function in patients with the antiphospholipid syndrome.

Vikerfors A, Svenungsson E, Ågren A, Mobarrez F, Bremme K, Holmström M, Eelde A, Bruzelius M, Elgue G, Wallén H, Antovic A.

Thromb Res. 2014 May;133(5):936-44. doi: 10.1016/j.thromres.2014.02.023. Epub 2014 Feb 28.

PMID:
24630645
20.

Thromboelastography (TEG®) compared to conventional coagulation tests in surgical patients--a laboratory evaluation.

Ågren A, Wikman AT, Holmström M, Östlund A, Edgren G.

Scand J Clin Lab Invest. 2013 Apr;73(3):214-20. doi: 10.3109/00365513.2013.765960. Epub 2013 Feb 12.

PMID:
23402666

Supplemental Content

Loading ...
Support Center